Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice

Beatrice Ondondo,a Sultan Abdul-Jawad,a Anne Bridgemeana, Tomáš Hankea,b

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdoma; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, The John Radcliffe, Oxford, United Kingdomb

A likely requirement for a protective vaccine against human immunodeficiency virus type 1 (HIV-1)/AIDS is, in addition to eliciting antibody responses, induction of effective T cells. To tackle HIV-1 diversity by T-cell vaccines, we designed an immunogen, HIVconsv, derived from the most functionally conserved regions of the HIV-1 proteome and demonstrated its high immunogenicity in humans and rhesus macaques when delivered by regimens combining plasmid DNA, nonreplicating simian (chimpanzee) adenovirus ChAdV-63, and nonreplicating modified vaccinia virus Ankara (MVA) as vectors. Here, we aimed to increase the decision power for iterative improvements of this vaccine strategy in the BALB/c mouse model. First, we found that prolonging the period after the ChAdV63.HIVconsv prime up to 6 weeks increased the frequencies of HIV-1-specific, gamma interferon (IFN-γ)-producing T cells induced by the MVA.HIVconsv boost. Induction of strong responses allowed us to map comprehensively the H-2d-restricted T-cell responses to these regions and identified 8 HIVconsv peptides, of which three did not contain a previously described epitope and were therefore considered novel. Induced effector T cells were oligofunctional and lysed sensitized targets in vitro. Our study therefore provides additional tools for studying and optimizing vaccine regimens in this commonly used small animal model, which will in turn guide vaccine improvements in more expensive nonhuman primate and human clinical trials.

The quest for a safe and effective vaccine against human immunodeficiency virus type 1 (HIV-1)/AIDS continues (1). Both prophylactic and particularly therapeutic vaccines will likely require induction of effective cytotoxic CD8+ T cells in addition to protective antibodies. There is strong evidence showing that HIV-1-specific CD8+ T cells contribute to the control of HIV-1 replication during acute and chronic stages of infection by killing virus-infected cells and by producing a number of soluble factors with antiviral activities (2). However, the initial CD8+ T-cell response, though strong, is typically directed toward a few immunodominant variable epitopes (3) often driving selection of virus escape mutations (4–6) and substantially contributing to the evolution of a large number of HIV-1 quasispecies detected in most infected individuals (7).

To tackle HIV-1 diversity and escape, we designed a novel immunogen, HIVconsv, assembled from the 14 most conserved regions of the HIV-1 proteome and encompassing consensus amino acid sequences derived from the four major alternating HIV-1 clades A, B, C, and D (8, 9). This immunogen was presented to the immune system using a variety of vaccine vectors such as plasmid DNA with and without electroporation, human and simian adenoviruses, poxvirus modified vaccinia virus Ankara (MVA), alphavirus Semliki Forest virus replicons, and modalities such as adjuvanted synthetic long peptides (9–15). These HIVconsv vaccines were used as a standalone delivery and more often in heterologous prime-boost regimens to enhance transgene product-specific responses while avoiding boost of responses against the delivery vectors. In human studies, conserved regions delivered by a combination of plasmid DNA pSG2.HIVconsv, simian (chimpanzee) adenovirus ChAdV63.HIVconsv, and MVA.HIVconsv elicited high frequencies of oligofunctional T-cell responses with broad specificities, which correlated with inhibition of 2 out of 8 tested HIV-1 isolates in an in vitro HIV-1 inhibition assay in the majority of vaccine recipients (16). While these initial preclinical and phase I clinical trial results are highly encouraging for the conserved region strategy, there is room for improvement, for example, in terms of the breadth of HIV-1 variant inhibition. Thus, vaccine modalities, conserved immunogen designs, regimens, routes of delivery, and adjuvantage will need to be modified and tested first in iterative preclinical studies to improve the vaccine performance.

To date, we have used predominantly a single immunodominant CD8+ T-cell epitope, H-2Dd- and Ld-restricted RGPGRAF KISV, designated P18-I10 (17,18) or historically by us as the HIV-1-derived immunogen HIVA and HIVconsv to inform vaccine development in the BALB/c mouse model (9, 20). The study presented here describes powering of this model for further vaccine and regimen improvements by detailed mapping of vaccine-induced T-cell specificities supported by functional characterization of the HIVconsv vaccine-induced cellular responses, which provides comprehensive and sensitive tools for further vaccine advances.

MATERIALS AND METHODS

Mouse immunizations. Six-week-old female BALB/c mice were immunized intramuscularly with doses of recombinant ChAdV63.HIVconsv or recombinant MVA.HIVconsv as indicated for each experiment. Animal

Received 8 September 2014 Accepted 12 September 2014
Published ahead of print 17 September 2014

Address correspondence to Tomáš Hanke, tomas.hanke@ndm.ox.ac.uk
Copyright © 2014 Ondondo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license.
doi:10.1128/CVI.00587-14

Copyright © 2014 Ondondo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license.
doi:10.1128/CVI.00587-14
FIG 1 Optimization of ChAdV63.HIVconsv-MVA.HIVconsv vaccine delivery. (A and B) Groups of BALB/c mice were immunized with indicated doses of either MVA.HIVconsv (A) or ChAdV63.HIVconsv (B), and responses to peptide H were assessed in an IFN-γ ELISPOT assay after 1 or 3 weeks, respectively. The dosage groups were significantly different with $P = 0.011$, $n = 5$ (A), and $P < 0.0001$, $n = 4$ (B). (C) Mice received a single injection of $10^7$ vp of ChAdV63.HIVconsv, and the induction of IFN-γ (black bars), CD107a (white bars), and TNF-α (gray bars)-positive cells at various time points after vaccine administration was determined using pooled PBMCs in an ICS assay after stimulation with peptide H. (D) The same mice were boosted with $10^6$ PFU of MVA.HIVconsv 1 week after the bleed, and control naive mice received MVA.HIVconsv alone without prior priming (M). Peptide H (black bars) and G1 (AMQMLKDTI; gray bars)-specific splenocytes were enumerated in an IFN-γ ELISPOT assay 1 week after administration of MVA.HIVconsv. Groups are significantly different with $P < 0.0001$, $n = 4$. Data for peptide H in panels A, B, and D were analyzed using one-way ANOVA, and column pairs were compared using a two-tailed unpaired $t$ test with Welch’s correction.
immunogenicity was measured by the frequency of HIVconsv-induced T cells recognizing the immunodominant H-2K\(^{\beta}\)/H-2L\(^{d}\)-restricted HIV-1 epitope H originating from the hypervariable loop 3 of Env (residues 311 to 320) (18, 19) in an IFN-\(\gamma\) ELISPOT assay. We found that the frequency of peptide H-specific T cells increased with increasing dose of MVA.HIVconsv, and at the highest dose of 10\(^8\) PFU, an average of 1,016 IFN-\(\gamma\)-spot-forming units (SFU)/10\(^6\) splenocytes were detected (Fig. 1A). Likewise, following ChAdV63.HIVconsv immunization, the frequency of IFN-\(\gamma\)-producing cells increased steadily with increasing vaccine dose and reached an average of 378 SFU/10\(^6\) splenocytes at a dose of 10\(^7\) virus particles (vp) (Fig. 1B). For subsequent experiments, ChAdV63.HIVconsv and MVA.HIVconsv vaccines were used at 10\(^8\) vp and 10\(^6\) PFU, respectively; we did not choose the maximum doses to avoid saturating the system, which might obscure detection of possible enhancements.

The overall magnitude of responses at 1 week after ChAdV63.HIVconsv immunization was much lower than that after MVA.HIVconsv immunization. We therefore sought to define the optimal time for achieving a peak multifunctional response following ChAdV63.HIVconsv administration. Groups of mice were immunized with a single dose of 10\(^8\) vp of ChAdV63.HIVconsv, and peptide H-specific T-cell responses in pooled PBMCs were determined using an intracellular cytokine staining (ICS) assay for IFN-\(\gamma\), CD107a, and TNF-\(\alpha\), at 1 to 5 weeks postimmunization. Indeed, vaccine-specific T-cell frequencies peaked at 20% of IFN-\(\gamma\)-CD8\(^+\) cells at week 5 after immunization (Fig. 1C), suggesting prolonged antigenic stimulation, possibly due to persistence of low levels of transcriptionally active ChAdV63.HIVconsv genomes, as previously described (21). One week after the bleed, the mice were boosted with 10\(^8\) PFU MVA. HIVconsv to assess the impact of the interval between the ChAdV63.HIVconsv prime and the MVA.HIVconsv boost on the magnitude of T-cell responses. A strong synergistic effect between the two vaccines, which peaked at 1,217 SFU/10\(^6\) splenocytes at a 6-week gap, was observed (Fig. 1D). These experiments indicated that a 5- to 6-week interval between the ChAdV63.HIVconsv prime and MVA.HIVconsv boost should be used for eliciting high frequencies of T-cell responses, which will in turn allow detailed mapping of subdominant epitopes. Subsequent experiments were thus performed using a 6-week interval.

Specificity mapping of HIVconsv-elicited T cells. We next assessed the magnitude, breadth, and functional spectrum of T-cell responses following the ChAdV63.HIVconsv-prime and MVA. HIVconsv-boost regimen (Fig. 2A), using 199 15-mer peptides overlapping by 11 amino acids (15/11) spanning the entire HIVconsv immunogen. These peptides were combined into pools P1 to P6 containing 32 to 35 individual 15/11 peptides and tested in an IFN-\(\gamma\) ELISPOT assay. High-magnitude responses to peptide pools P2, P4, and P6 were detected (Fig. 2B), thus further confirming the synergistic effect of ChAdV63.HIVconsv and MVA.HIVconsv vaccines. Mapping of the single peptides in each pool confirmed a high-frequency response to epitope H contained in peptides 197/198, which reached for the latter an average of 2,354 SFU/10\(^6\) splenocytes, and revealed two other dominant responses averaging 1,235 and 1,635 SFU/10\(^6\) cells for peptides 42 (Gag amino acids 126 to 140) and 112 (Pol amino acids 174 to 186/560-561, i.e., containing a two-region junction), respectively. Also, peptides 9, 15, 55, 151, and 164 induced weaker, but definite, positive vaccine-elicited responses (Fig. 2C), which may not have been detected using a less potent regimen (10, 22). These responses were confirmed in an independent experiment yielding average frequencies of 163, 210, 199, 90, and 180 SFU/10\(^6\) splenocytes, respectively (Fig. 2D). Peptide 9 (VGGHQAAMQMLK DTI) contains a known epitope; while the AMQMLKETI is the index epitope (23, 24), the AMQMLKDTI variant present in the vaccine is much weaker (10, 24), which likely explains its low immunogenicity in these experiments. Peptides 42 (KAIGTVLY GPTPVNI), 151 (VHVASGYIEAVIPA), and 164 (VQMAYFIH NFKRGGI) do not contain any known epitope and are therefore considered novel. Optimal epitope mapping for peptides 42 and 112 using sequentially truncated peptides identified the respective 9-mer binding epitopes as LGKPTVNI and YDYPKLDI (Fig. 2E). Thus, the ChAdV63.HIVconsv-MVA.HIVconsv (CM) regimen elicited broadly specific T-cell responses.

ChAdV63.HIVconsv-MVA.HIVconsv regimen induces oligofunctional T cells. The functional diversity of HIVconsv-specific T cells elicited by the ChAdV63.HIVconsv-MVA.HIVconsv regimen was assessed using the ICS assay. Examples of dot plots for the 3 immunodominant epitopes are shown in Fig. 3A. As expected, the total frequencies of CD8\(^+\) T cells expressing CD107a, IFN-\(\gamma\), or TNF-\(\alpha\) functions were dominated by peptide pool P6 (Fig. 3B), which contains the immunodominant peptide H. This peptide pool showed a remarkably high frequency of specific degranulating CD107a\(^+\) CD8\(^+\) T cells, which exceeded 20% of the total CD8\(^+\) T cells. Strong responses to peptide pools P2 and P4 were also observed (Fig. 3B). Characterization of CD8\(^+\) T-cell polyfunctionality for peptide pools P2, P4, and P6 revealed that a large proportion of the responding cells expressed all three functions comprising CD107a, TNF-\(\alpha\), and IFN-\(\gamma\) (Fig. 3C). We further assessed the cytotoxic potential of HIVconsv-induced T cells in an ex vivo killing assay using peptide-pulsed cells as targets and demonstrated that freshly harvested, unstimulated splenocytes could efficiently kill peptide-pulsed P815 target cells, achieving medians of 44%, 47%, and 79% lysis of target cells sensitized with peptides 42, 112, and H, respectively, at an effector-to-target cell ratio of 10:1 (Fig. 4). These lysis data concur with the high frequency of degranulating CD107a\(^+\) CD8\(^+\) T cells observed in Fig. 3B and C and further define the functionality of HIVconsv-specific effector T cells.

**DISCUSSION**

Nonreplicating vaccine vectors for delivery of pathogen-derived subunit immunogens are in the forefront of vaccine development for many infections. These vectors are most efficiently used in heterologous prime-boost regimens to avoid buildup of antivector antibodies, which dampen induction of immune responses against the transgene product (8). Although some general rules for combining heterologous vectors into a prime-boost regimen are emerging, optimization of vaccination regimens is mostly empirical. Incremental vaccination improvements are best assessed first in small-animal models such as the BALB/c mice.

This study indicated an ongoing expansion of ChAdV63.HIVconsv-elicited T-cell frequencies for at least 6 weeks postadministration. This was also reflected in the requirement for a long interval of 5 to 6 weeks after ChAdV63.HIVconsv priming to achieve high frequencies of HIVconsv-specific T cells by an MVA.HIVconsv boost and confirmed the impressive immunogenicity of a simple hetero-
FIG 2 Breadth, magnitude, and fine specificity of T-cell responses induced by the HIVconsv vaccines. (A) Immunization schedule of BALB/c mice: C and M represent 10^8 vp of ChAdV63.HIVconsv and 10^6 PFU of MVA.HIVconsv, respectively. (B and C) Splenocytes were tested for IFN-γ production in an ELISPOT assay upon restimulation with peptide pools P1 to P6 (B) or individual 15/11 HIVconsv peptides derived from the HIVconsv immunogen (C). Data in panel B are represented as means ± standard errors of the means, n = 4 (mice); panel C shows means ± standard errors of the means, n = 3 (triplicate of pooled samples), with one-way ANOVA, P < 0.0001. (D) An independent experiment using the same CM regimen for immunization confirmed responses induced to the 8 peptides identified in panel C with the one-way ANOVA, P < 0.0001. (E) Mapping of minimal epitopes for peptide 42, corresponding to Gag amino acids 126 to 140, and peptide 112, corresponding to Pol amino acids 174 to 186/560-561 (containing a two-region junction), of the HXB2 sequence using progressively truncated peptides in an IFN-γ ELISPOT assay. Pooled splenocyte samples were employed as effectors.
ologous ChAdV63-prime and MVA-boost regimen observed in humans (16, 25, 26).

A comprehensive screening of peptides covering the entire HIVconsv immunogen identified several novel H-2d-restricted immunogenic regions recognized by the BALB/c mice. While the specificities of the stronger epitopes were described before (18, 27–29), responses to peptides 42, 151, and 164 would likely be missed using a vaccine delivery weaker than the CM regimen. This information increases the analysis “granularity” of T cells elicited by the conserved region as well as other HIV-1 vaccine candidates. More detailed and comprehensive study of cell-mediated responses aids further iterative improvements of the magnitude, breadth, functionality, and longevity of this important arm of immune defenses against microorganisms and may help shed light on more fundamental questions such as immunodominance and antigen processing.

Given the differences between the H-2d and HLA major histocompatibility complex molecules, only some peptides immuno-

FIG 3 Functional characterization of T cells stimulated by the HIVconsv vaccines. BALB/c mice were vaccinated by the ChAdV63.HIVconsv-MVA.HIVconsv regimen. One week after MVA.HIVconsv, oligofunctional profiles of HIVconsv-elicited T cells were assessed by ICS assay. (A) Representative FACS plots for TNF-α or CD107a versus IFN-γ in response to peptides H, 42, and 112. (B) Frequencies of CD8⁺ T cells expressing TNF-α, CD107a, or IFN-γ upon stimulation using either peptide pools P1 to P6 (left) or individual peptides 42, 112, and H (right). Data are represented as means ± standard errors of the means (n = 3). (C) Oligofunctional profiles of CD8⁺ T cells specific for peptide pools P2, P4, and P6. Data are represented as means (n = 3). The intragroup variations were low as shown in panel B and were not plotted for this analysis.
genic in the BALB/c mouse are also presented by the human HLAs. Thus, peptide H is unusual in that it has four anchor residues for H-2Dd (30, 31) and displays “promiscuous” binding to four different H-2Dd, H-2Dp, H-2u, and H-2q murine determinants (32) as well as human HLA-A2 (33), although in our hands, in human volunteers (16, 34–43) or HLA-A2-transgenic HHD mice (unpublished data), such responses were never detected for either the HIVA (20) or the HIVconsV (9) immunogens. No responses were detected in 23 human recipients of the HIVconsV vaccine to peptide 42 or 112, while T cells were induced to peptides 151 and 164 (16). Although not directly comparable or translatable between mouse and humans, these results increase the confidence about the usefulness of optimizing new vaccine strategies first in a small and well-defined model.

**FIG 4** Cytotoxic potential of peptide 42-, 112-, and H-specific T cells induced by the HIVconsV vaccines. BALB/c mice were immunized with ChAdV63.HIVconsV followed by MVA.HIVconsV as shown in Fig. 2A. One week after MVA.HIVconsV, the splenocytes were tested for their potential to kill peptide-pulsed P815 cell targets. (A) Representative FACS plots showing the gating strategy. SSC, side scatter; FSC, forward scatter. (B) Percent specific lysis of peptide-pulsed P815 target cells at an effector-to-target ratio of 10:1 (left panel) or 5:1 (right panel). The horizontal lines represent the medians.
REFERENCES

1. McMichael AJ, Haynes BF. 2012. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 13:423–427. http://dx.doi.org/10.1038/ni.2264.

2. Walker B, McMichael A. 2012. The T-cell response to HIV. Cold Spring Harb. Perspect. Med. 2:a007054. http://dx.doi.org/10.1101/cshperspect.a007054.

3. Bansal A, Gough E, Sabbaj S, Ritter D, Yusim K, Sklaianos G, Al-drovandi G, Kaslow RA, Wilson CM, Mulligan MJ, Kilby JM, Goepert PA. 2005. CD8 T-cell responses in early HIV-1 infection are skewed towards highly encephalitogenic peptides. AIDS 19:241–250.

4. Alfredt M, Kalife ET, Qi Y, Streeck H, Johnston MN, Liljestrom P. 2012. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 13:423–427. http://dx.doi.org/10.1038/ni.2264.

5. McMichael AJ, Haynes BF. 2012. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 13:423–427. http://dx.doi.org/10.1038/ni.2264.

6. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Dorrell L, Bontrop RE, Wagner R, Williamson C, Williamson A-L, McMichael AJ. 2009. The first T-cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253–1272. http://dx.doi.org/10.1084/jem.20090365.

7. Altfeld M, Bridgerman A, Quakklelaar ED, Quigley MF, Hill BJ, Knudsen ML, Ammedova V, Ljungberg K, Borthwick N, Im EI, McMichael AJ, Drijfhout JW, Newan HY, Venturi V, Douek DC, Colloca S, Liljestrom P, Nieuwenhuis I, Doxiadis G, Mooij P, Weinhold KJ, Moore S, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Bontrop RE, Perelson AS, Ahan BH, Shaw GM, Korber BT, McMichael AJ. 2009. The first T-cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253–1272. http://dx.doi.org/10.1084/jem.20090365.

8. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganousov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Bontrop RE, Perelson AS, Ahan BH, Shaw GM, Korber BT, McMichael AJ. 2009. The first T-cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253–1272. http://dx.doi.org/10.1084/jem.20090365.
27. Mata M, Travers PJ, Liu Q, Frankel FR, Paterson Y. 1998. The MHC class I-restricted immune response to HIV gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J. Immunol. 161:2985–2993.

28. Achour A, Persson K, Harris RA, Sundberg J, Sentman CL, Lindqvist Y, Schneider G, Karre K. 1998. The crystal structure of H-2Dd MHC class I complexed with the HIV-1-derived peptide P18-I10 at 2.4 Å resolution: implications for T cell and NK cell recognition. Immunity 9:199–208. http://dx.doi.org/10.1016/S1074-7613(00)80602-0.

29. Li H, Natarajan K, Malchiodi EL, Margulies DH, Mariuzza RA. 1998. Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120. J. Mol. Biol. 283:179–191. http://dx.doi.org/10.1006/jmbi.1998.2091.

30. Shira M, Pendleton CD, Berzofsky JA. 1992. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. J. Immunol. 148:1657–1667.

31. Alexander-Miller MA, Parker KC, Tsukui T, Pendleton CD, Coligan JE, Berzofsky JA. 1996. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Int. Immunol. 8:641–649. http://dx.doi.org/10.1093/intimm/8.5.641.

32. Alfolabi MO, Ndure J, Drammeh A, Darboe F, Mehedi S-R, Rowland-Jones SL, Borthwick N, Black A, Ambler G, John-Stewart GC, Reilly M, Hanke T, Flanagan KL. 2013. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS One 8:e78289. http://dx.doi.org/10.1371/journal.pone.0078289.

33. Dorrell L, Yang H, Iversen AK, Conlon C, Suttil A, Lancaster M, Dong T, Cebere I, Edwards A, Rowland-Jones S, Hanke T, McMichael AJ. 2005. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 19:1321–1323. http://dx.doi.org/10.1097071.aid.s00018104.65640.16.

34. Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, Suttil A, Conlon C, Brown D, Williams P, Bowness P, Goonetilleke N, Rostron T, Rowland-Jones S, Hanke T, McMichael AJ. 2006. Expansion and diversification of HIV-1-specific T cells following immunisation of HIV-1-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 gag vaccine. J. Virol. 80:4705–4716. http://dx.doi.org/10.1128/JVI.80.10.4705-4716.2006.

35. Goonetilleke N, Moore S, Dally L, Winstone N, Mahmoud N, Cebere I, Pinheiro S, Gillespie G, Brown D, Louch V, Roberts J, Guimaraes-Walker A, Hayes P, Loughran K, Smith C, Fast P, Dorrell L, Hanke T, McMichael A. 2006. Prime-boost vaccination with recombinant DNA and MVA expressing HIV-1 clade A gag and immunodominant CTL epitopes induces multi-functional HIV-1-specific T cells in healthy subjects. J. Virol. 80:4717–4728. http://dx.doi.org/10.1128/JVI.80.10.4717-4728.2006.

36. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, Bashar F, Bhatt K, Ogutu H, Wakasiaka S, Matu L, Wariungi W, Odda J, Oyaro M, Indangasi J, Ndiyini-Achola J, Konde C, Mugisha E, Fast P, Schmidt C, Gilmore J, Tarragona T, Smith C, Barin B, Dally L, Johnson B, Muluubya A, Nielsen L, Hayes P, Boaz M, Hughes P, Hanke T, McMichael A, Bwayo J, Kaleebu P. 2008. Safety and immunogenicity of recombinant low-dose HIV-1 A vaccine candidates vectorized by plasmid pH12 or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26:2788–2795. http://dx.doi.org/10.1016/j.vaccine.2008.02.071.

37. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wei EG, Beattie T, Chen Y-H, Dorrel L, McShane H, Schmidt C, Brooks M, Patel S, Roberts J, Conlon C, Rowland-Jones S, Bwayo J, McMichael AJ, Hanke T. 2004. An HIV-1 clade A vaccine in clinical trials: stimulation of HIV-specific T cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85:911–919. http://dx.doi.org/10.1099/vir.0.19701-0.

38. Njuguna IN, Ambler G, Reilly M, Ondondo B, Kanyugo M, Lohman-Payne B, Gichuhi C, Borthwick N, Black A, Mehedi S-R, Maleche-Obimbo E, Chohan B, John-Stewart GC, Jaoko W, Hanke T. 27 August 2014. PedVacc 002: a phase I randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-infected mothers in Nairobi. Vaccine http://dx.doi.org/10.1016/j.vaccine.2014.08.034.

39. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmore J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinsiks I, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantea G, Hanke T, Bwayo J. 2007. Studies of a prophylactic HIV-1 candidate vaccine based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25:2120–2127. http://dx.doi.org/10.1016/j.vaccine.2006.11.016.

40. Winstone N, Guimaraes-Walker A, Roberts J, Brown D, Loach V, Goonetilleke N, Hanke T, McMichael AJ. 2009. Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-MVA vaccinated human volunteers by cultured IFN-γ ELISPOT assay. Eur. J. Immunol. 39:975–985. http://dx.doi.org/10.1002/eji.200839167.

41. Yang H, Dong T, Turnbull E, Ranasinghe S, Ondondo B, Goonetilleke N, Winstone N, di Gleria K, Bowness P, Conlon C, Borrow P, Hanke T, McMichael A, Dorrell L. 2007. Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy. J. Immunol. 179:597–606. http://dx.doi.org/10.4049/jimmunol.179.1.597.

42. Ewer KJ, O’Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halsted FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blaghorough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV. 2013. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adeovirus-MVA immunisation. Nat. Commun. 4:2836. http://dx.doi.org/10.1038/ncomms3836.

43. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halsted FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie E, Moyle S, Gantlett K, Colloca S, Cortese R, Long CA, Sinden RE, Gilbert SC, Lawrie AM, Doherty T, Faust SN, Nicosia A, Hill AV, Draper SJ. 2012. ChAd63-MVA-vectorised blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20:2355–2368. http://dx.doi.org/10.1038/mt.2012.223.